Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Liposic EDO is a highly viscous ophthalmic gel formulated for the symptomatic treatment of dry eye syndrome. Its primary active ingredient is carbomer, which acts as a tear substitute and lubricant by forming a protective and moisturizing layer over the ocular surface. This gel mimics natural tears by stabilizing all three layers of the tear film—lipid, aqueous, and mucin—providing long-lasting relief from irritation, burning, or tiredness associated with dry eyes. The formulation also includes cetrimide (as preservative), sorbitol, medium-chain triglycerides for enhanced viscosity and comfort, sodium hydroxide for pH adjustment to match natural tears (pH 7.4), and purified water[1][2][3]. It is particularly suitable for moderate to severe dry eye symptoms and can be used multiple times daily but should not be applied while wearing contact lenses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Liposic EDO.